Search

Your search keyword '"Iaffaldano P."' showing total 14 results
Start Over Author "Iaffaldano P." Journal journal of neurology
14 results on '"Iaffaldano P."'

1. Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)

Author

Chisari, Clara Grazia, Amato, Maria Pia, Di Sapio, Alessia, Foschi, Matteo, Iaffaldano, Pietro, Inglese, Matilde, Fermo, Salvatore Lo, Lugaresi, Alessandra, Lus, Giacomo, Mascoli, Nerina, Montepietra, Sara, Pesci, Ilaria, Quatrale, Rocco, Salemi, Giuseppe, Torri Clerici, Valentina, Totaro, Rocco, Valentino, Paola, Filippi, Massimo, and Patti, Francesco

Published
2024
Full Text
View/download PDF

2. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis

Author

Simone, Marta, Lucisano, Giuseppe, Guerra, Tommaso, Paolicelli, Damiano, Rocca, Maria A., Brescia Morra, Vincenzo, Patti, Francesco, Annovazzi, Pietro, Gasperini, Claudio, De Luca, Giovanna, Ferraro, Diana, Margari, Lucia, Granella, Franco, Pozzilli, Carlo, Romano, Silvia, Perini, Paola, Bergamaschi, Roberto, Coniglio, Maria Gabriella, Lus, Giacomo, Vianello, Marika, Lugaresi, Alessandra, Portaccio, Emilio, Filippi, Massimo, Amato, Maria Pia, and Iaffaldano, Pietro

Published
2024
Full Text
View/download PDF

3. Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression

Author

Portaccio, Emilio, Betti, Matteo, De Meo, Ermelinda, Addazio, Ilaria, Pastò, Luisa, Razzolini, Lorenzo, Totaro, Rocco, Spitaleri, Daniele, Lugaresi, Alessandra, Cocco, Eleonora, Onofrj, Marco, Di Palma, Franco, Patti, Francesco, Maimone, Davide, Valentino, Paola, Clerici, Valentina Torri, Protti, Alessandra, Ferraro, Diana, Lus, Giacomo, Maniscalco, Giorgia Teresa, Morra, Vincenzo Brescia, Salemi, Giuseppe, Granella, Franco, Pesci, Ilaria, Bergamaschi, Roberto, Aguglia, Umberto, Vianello, Marika, Simone, Marta, Lepore, Vito, Iaffaldano, Pietro, Comi, Giancarlo, Filippi, Massimo, Trojano, Maria, and Amato, Maria Pia

Published
2024
Full Text
View/download PDF

4. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression

Author

Portaccio, Emilio, Betti, Matteo, De Meo, Ermelinda, Addazio, Ilaria, Pastò, Luisa, Razzolini, Lorenzo, Totaro, Rocco, Spitaleri, Daniele, Lugaresi, Alessandra, Cocco, Eleonora, Onofrj, Marco, Di Palma, Franco, Patti, Francesco, Maimone, Davide, Valentino, Paola, Torri Clerici, Valentina, Protti, Alessandra, Ferraro, Diana, Lus, Giacomo, Maniscalco, Giorgia Teresa, Brescia Morra, Vincenzo, Salemi, Giuseppe, Granella, Franco, Pesci, Ilaria, Bergamaschi, Roberto, Aguglia, Umberto, Vianello, Marika, Simone, Marta, Lepore, Vito, Iaffaldano, Pietro, Comi, Giancarlo, Filippi, Massimo, Trojano, Maria, and Amato, Maria Pia

Published
2024
Full Text
View/download PDF

5. Big Multiple Sclerosis Data network: an international registry research network

Author

Glaser, Anna, Butzkueven, Helmut, van der Walt, Anneke, Gray, Orla, Spelman, Tim, Zhu, Chao, Trojano, Maria, Iaffaldano, Pietro, Battaglia, Mario A., Lucisano, Giuseppe, Vukusic, Sandra, Vukusic, Irena, Casey, Romain, Horakova, Dana, Drahota, Jiri, Magyari, Melinda, Joensen, Hanna, Pontieri, Luigi, Elberling, Frederik, Klyve, Pernilla, Mouresan, Elena Flavia, Forsberg, Lars, and Hillert, Jan

Published
2024
Full Text
View/download PDF

7. Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry

Author

Lorefice, Lorena, Ferraro, Ottavia Elena, Fenu, Giuseppe, Amato, Maria Pia, Bresciamorra, Vincenzo, Conte, Antonella, De Luca, Giovanna, Ferraro, Diana, Filippi, Massimo, Gazzola, Paola, Iaffaldano, Pietro, Inglese, Matilde, Lus, Giacomo, Marfia, Girolama Alessandra, Patti, Francesco, Pesci, Ilaria, Salemi, Giuseppe, Trojano, Maria, Zaffaroni, Mauro, Monti, Maria Cristina, and Cocco, Eleonora

Published
2024
Full Text
View/download PDF

8. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Author

Iaffaldano, Pietro, Lucisano, Giuseppe, Guerra, Tommaso, Patti, Francesco, Cocco, Eleonora, De Luca, Giovanna, Brescia Morra, Vincenzo, Pozzilli, Carlo, Zaffaroni, Mauro, Ferraro, Diana, Gasperini, Claudio, Salemi, Giuseppe, Bergamaschi, Roberto, Lus, Giacomo, Inglese, Matilde, Romano, Silvia, Bellantonio, Paolo, Di Monte, Elisabetta, Maniscalco, Giorgia Teresa, Conte, Antonella, Lugaresi, Alessandra, Vianello, Marika, Torri Clerici, Valentina Liliana Adriana, Di Sapio, Alessia, Pesci, Ilaria, Granella, Franco, Totaro, Rocco, Marfia, Girolama Alessandra, Danni, Maura Chiara, Cavalla, Paola, Valentino, Paola, Aguglia, Umberto, Montepietra, Sara, Ferraro, Elisabetta, Protti, Alessandra, Spitaleri, Daniele, Avolio, Carlo, De Riz, Milena, Maimone, Davide, Cavaletti, Guido, Gazzola, Paola, Tedeschi, Gioacchino, Sessa, Maria, Rovaris, Marco, Di Palma, Franco, Gatto, Maurizia, Cargnelutti, Daniela, De Robertis̄, Francesca, Logullo, Francesco Ottavio, Rini, Augusto, Meucci, Giuseppe, Ardito, Bonaventura, Banfi, Paola, Nasuelli, Davide, Paolicelli, Damiano, Rocca, Maria Assunta, Portaccio, Emilio, Chisari, Clara Grazia, Fenu, Giuseppe, Onofrj, Marco, Carotenuto, Antonio, Ruggieri, Serena, Tortorella, Carla, Ragonese, Paolo, Nica, Mihaela, Amato, Maria Pia, Filippi, Massimo, and Trojano, Maria

Published
2024
Full Text
View/download PDF

10. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

Author

Chisari, Clara G., Comi, Giancarlo, Filippi, Massimo, Paolicelli, Damiano, Iaffaldano, Pietro, Zaffaroni, Mauro, Brescia Morra, Vincenzo, Cocco, Eleonora, Marfia, Girolama Alessandra, Grimaldi, Luigi Maria, Inglese, Matilde, Bonavita, Simona, Lugaresi, Alessandra, Salemi, Giuseppe, De Luca, Giovanna, Cottone, Salvatore, Conte, Antonella, Sola, Patrizia, Aguglia, Umberto, Maniscalco, Giorgia Teresa, Gasperini, Claudio, Ferrò, Maria Teresa, Pesci, Ilaria, Amato, Maria Pia, Rovaris, Marco, Solaro, Claudio, Lus, Giacomo, Maimone, Davide, Bergamaschi, Roberto, Granella, Franco, Di Sapio, Alessia, Bertolotto, Antonio, Totaro, Rocco, Vianello, Marika, Cavalla, Paola, Bellantonio, Paolo, Lepore, Vito, and Patti, Francesco

Published
2022
Full Text
View/download PDF

12. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.

Author

Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, and Trojano M

Subjects
Adult, Drug Administration Schedule, Female, Fingolimod Hydrochloride administration & dosage, Humans, Immunologic Factors administration & dosage, Interferon beta-1a administration & dosage, Italy, Male, Middle Aged, Retrospective Studies, Disease Progression, Fingolimod Hydrochloride pharmacology, Immunologic Factors pharmacology, Interferon beta-1a pharmacology, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis, Relapsing-Remitting physiopathology, Outcome Assessment, Health Care, Registries, Severity of Illness Index
Abstract

Background: The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies., Objective: To evaluate different therapeutic strategies and their long-term outcomes, measured as relapses and confirmed disability progression (CDP), in MS 'real-world' settings., Methods: Multicentre, observational, retrospectively acquired cohort study evaluating the long-term impact of different treatment strategies on disability outcomes in patients with RMS in the Italian MS Register., Results: We evaluated 1152 RMS-naïve patients after propensity-score adjustment. Patients included were receiving: interferon beta-1a (IFN-β1a) 44 µg switching to fingolimod (FTY; IFN-switchers; n = 97); FTY only (FTY-stayers; n = 157); IFN-β1a only (IFN-stayers; n = 849). CDP and relapses did not differ between FTY-stayers and IFN-switchers [HR (95% CI) 0.99 (0.48-2.04), p = 0.98 and 0.81 (0.42-1.58), p = 0.55, respectively]. However, IFN-stayers showed increased risk of relapses compared with FTY-stayers [HR (95% CI) 1.46 (1.00-2.12), p = 0.05]., Conclusion: The ideal treatment option for MS is becoming increasingly complex, with the need to balance benefit and risks. Our results suggest that starting with FTY affects the long-term disease outcome similarly to escalating from IFN-β1a to FTY.

Published
2019
Full Text
View/download PDF

13. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.

Author

Iaffaldano P, Viterbo RG, and Trojano M

Subjects
Adult, Cognition Disorders drug therapy, Disability Evaluation, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis diagnostic imaging, Neuropsychological Tests, Statistics, Nonparametric, Young Adult, Cognition Disorders etiology, Immunologic Factors therapeutic use, Multiple Sclerosis complications, Multiple Sclerosis drug therapy, Natalizumab therapeutic use, Substance Withdrawal Syndrome etiology
Abstract

Natalizumab discontinuation is associated with a disease reactivation in multiple sclerosis (MS) patients. Whether this reactivation involves also cognitive functions is not known to date. To assess the persistence of the effect of natalizumab on cognitive functions 1 year after its discontinuation, we compared the longitudinal changes of cognitive performances in two groups of patients. The interrupters, 30 MS patients, have stopped natalizumab due to PML concern, and the continuers, 28 MS patients, continued the treatment. The cognitive impairment index (CII) was used as main outcome measure. As expected, during the natalizumab treatment, we observed a significant reduction of the relapse rate and the number of gadolinium-enhancing lesions along with a reduction of the CII. After 1 year of discontinuation, the beneficial effect on cognitive functions was lost in the interrupters group, as the mean CII increased in comparison with the mean at the end of natalizumab treatment (12.2 ± 7.9 vs 9.3 ± 8.1, p < 0.0001). As opposite, in the continuers group, the CII further decreased after an additional year of treatment (8.4 ± 5.1 vs 9.8 ± 4.6, p = 0.007). A multivariate logistic regression model revealed as predictors of cognitive worsening male sex, disease duration, and the treatment discontinuation. The worsening of cognitive functions after natalizumab discontinuation goes in parallel with the clinical/radiological disease reactivation. Our data reinforce the hypothesis that, in the short-term, natalizumab exerts its positive impact on cognitive functions by means of its anti-inflammatory properties.

Published
2016
Full Text
View/download PDF

14. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender.

Author

Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Paolicelli D, Livrea P, and Trojano M

Subjects
Adolescent, Adult, Aged, Chromatography, High Pressure Liquid, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Young Adult, Biomarkers blood, Homocysteine blood, Multiple Sclerosis blood
Abstract

Elevated homocysteine (Hcy) levels exert several neurotoxic actions and vascular dysfunctions that may be involved in pathogenesis and progression of multiple sclerosis (MS). The effective role of Hcy in MS however remains to be determined. The aim of this work was to compare plasma Hcy levels in MS patients and neurological disease controls (NDC) and to evaluate their relationships with clinical and demographic variables. In this cross-sectional study, we examined plasma Hcy levels in 217 patients with MS [53 clinically isolated syndromes (CIS) suggestive of MS, 134 relapsing remitting (RR), 23 secondary progressive (SP) and seven primary progressive (PP) MS], recruited among patients attending a tertiary clinical center in southern Italy and in 219 age/sex-matched controls. Median Hcy levels were slightly higher in MS patients compared to NDC (9.1 μmol/l; range, 3.4-35.9 vs. 8.6, range 3.5-27.4; p = 0.02). Median Hcy concentrations were increased in males more than in females in the MS population (10.4 vs. 8.4; p < 0.0001), whereas no differences across genders were found in NDC (9.1 vs. 8.5). Hcy levels were higher in male MS patients compared to the male NDC patients (p = 0.001). Patients with CIS had lower Hcy (7.5 μmol/l; p = 0.004) compared to patients with RR (9.5 μmol/l), SP (10.1 μmol/l) and PP (9.9 μmol/l). Median Hcy concentration was higher in patients with disease duration longer than 22 months (9.7 vs. 8.6 μmol/l; p = 0.02). Plasma Hcy levels are increased in patients with definite MS. Higher Hcy levels are associated with male sex, suggesting a role of Hcy in neurodegenerative processes of MS, which are prominent in male patients.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results